Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1á and FOXO3a by AMPK signaling

Ji Hae Kim, Jung Ok Lee, Nami Kim, Hye Jeong Lee, Yong Woo Lee, Hyung Ip Kim, Su Jin Kim, Sun-Hwa Park, Hyeon Soo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Paclitaxel (Taxol), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used for treating ovarian, lung and breast cancers. Currently, there is little information regarding the specific mechanism underlying the anticancer activity of paclitaxel. In the present study, we found that 5-amino-1-β-D-ribofuranosylimidazole.4.carboxamide (AICAR), a well-known activator of adenosine monophosphate (AMP)-activated protein kinase (AMPK), downregulated the protein and mRNA levels of elongation factor 1 α (EF1α) in breast cancer MCF7 cells. Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1α in MCF7 cells. In addition, paclitaxel increased the expression, as well as the phosphorylation of forkhead box O3a (FOXO3a). Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation. The induction and phosphorylation of FOXO3a by paclitaxel were not observed in EF1α and AMPK knockdown cells. Co-treatment with AICAR resulted in increased susceptibility of cancer cells to paclitaxel-induced suppression of their viability and further enhanced paclitaxel.induced FOXO3a phosphorylation. These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1¿/FOXO3a signaling pathway.

Original languageEnglish
Pages (from-to)1874-1880
Number of pages7
JournalInternational Journal of Oncology
Volume47
Issue number5
DOIs
Publication statusPublished - 2015 Nov 1

Fingerprint

Peptide Elongation Factor 1
AMP-Activated Protein Kinases
MCF-7 Cells
Paclitaxel
Breast Neoplasms
Phosphorylation
Down-Regulation
Adenosine Monophosphate
Protein Kinase Inhibitors
Ovarian Neoplasms
Protein Kinases
Lung Neoplasms

Keywords

  • Adenosine monophosphate-activated protein kinase
  • Elongation factor 1 α
  • Forkhead box O3a
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1á and FOXO3a by AMPK signaling. / Kim, Ji Hae; Lee, Jung Ok; Kim, Nami; Lee, Hye Jeong; Lee, Yong Woo; Kim, Hyung Ip; Kim, Su Jin; Park, Sun-Hwa; Kim, Hyeon Soo.

In: International Journal of Oncology, Vol. 47, No. 5, 01.11.2015, p. 1874-1880.

Research output: Contribution to journalArticle

Kim, Ji Hae ; Lee, Jung Ok ; Kim, Nami ; Lee, Hye Jeong ; Lee, Yong Woo ; Kim, Hyung Ip ; Kim, Su Jin ; Park, Sun-Hwa ; Kim, Hyeon Soo. / Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1á and FOXO3a by AMPK signaling. In: International Journal of Oncology. 2015 ; Vol. 47, No. 5. pp. 1874-1880.
@article{7ea29e82d42f4bb9806336462e8145c3,
title = "Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1{\'a} and FOXO3a by AMPK signaling",
abstract = "Paclitaxel (Taxol), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used for treating ovarian, lung and breast cancers. Currently, there is little information regarding the specific mechanism underlying the anticancer activity of paclitaxel. In the present study, we found that 5-amino-1-β-D-ribofuranosylimidazole.4.carboxamide (AICAR), a well-known activator of adenosine monophosphate (AMP)-activated protein kinase (AMPK), downregulated the protein and mRNA levels of elongation factor 1 α (EF1α) in breast cancer MCF7 cells. Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1α in MCF7 cells. In addition, paclitaxel increased the expression, as well as the phosphorylation of forkhead box O3a (FOXO3a). Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation. The induction and phosphorylation of FOXO3a by paclitaxel were not observed in EF1α and AMPK knockdown cells. Co-treatment with AICAR resulted in increased susceptibility of cancer cells to paclitaxel-induced suppression of their viability and further enhanced paclitaxel.induced FOXO3a phosphorylation. These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1¿/FOXO3a signaling pathway.",
keywords = "Adenosine monophosphate-activated protein kinase, Elongation factor 1 α, Forkhead box O3a, Taxol",
author = "Kim, {Ji Hae} and Lee, {Jung Ok} and Nami Kim and Lee, {Hye Jeong} and Lee, {Yong Woo} and Kim, {Hyung Ip} and Kim, {Su Jin} and Sun-Hwa Park and Kim, {Hyeon Soo}",
year = "2015",
month = "11",
day = "1",
doi = "10.3892/ijo.2015.3153",
language = "English",
volume = "47",
pages = "1874--1880",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Paclitaxel suppresses the viability of breast tumor MCF7 cells through the regulation of EF1á and FOXO3a by AMPK signaling

AU - Kim, Ji Hae

AU - Lee, Jung Ok

AU - Kim, Nami

AU - Lee, Hye Jeong

AU - Lee, Yong Woo

AU - Kim, Hyung Ip

AU - Kim, Su Jin

AU - Park, Sun-Hwa

AU - Kim, Hyeon Soo

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Paclitaxel (Taxol), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used for treating ovarian, lung and breast cancers. Currently, there is little information regarding the specific mechanism underlying the anticancer activity of paclitaxel. In the present study, we found that 5-amino-1-β-D-ribofuranosylimidazole.4.carboxamide (AICAR), a well-known activator of adenosine monophosphate (AMP)-activated protein kinase (AMPK), downregulated the protein and mRNA levels of elongation factor 1 α (EF1α) in breast cancer MCF7 cells. Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1α in MCF7 cells. In addition, paclitaxel increased the expression, as well as the phosphorylation of forkhead box O3a (FOXO3a). Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation. The induction and phosphorylation of FOXO3a by paclitaxel were not observed in EF1α and AMPK knockdown cells. Co-treatment with AICAR resulted in increased susceptibility of cancer cells to paclitaxel-induced suppression of their viability and further enhanced paclitaxel.induced FOXO3a phosphorylation. These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1¿/FOXO3a signaling pathway.

AB - Paclitaxel (Taxol), a potent drug of natural origin isolated from the bark of the Pacific yew, is widely used for treating ovarian, lung and breast cancers. Currently, there is little information regarding the specific mechanism underlying the anticancer activity of paclitaxel. In the present study, we found that 5-amino-1-β-D-ribofuranosylimidazole.4.carboxamide (AICAR), a well-known activator of adenosine monophosphate (AMP)-activated protein kinase (AMPK), downregulated the protein and mRNA levels of elongation factor 1 α (EF1α) in breast cancer MCF7 cells. Paclitaxel increased the phosphorylation of AMPK and also downregulated the expression of EF1α in MCF7 cells. In addition, paclitaxel increased the expression, as well as the phosphorylation of forkhead box O3a (FOXO3a). Phosphorylation of FOXO3a was suppressed in the presence of compound C, a specific AMPK inhibitor, suggesting the involvement of AMPK in paclitaxel-induced FOXO3a phosphorylation. The induction and phosphorylation of FOXO3a by paclitaxel were not observed in EF1α and AMPK knockdown cells. Co-treatment with AICAR resulted in increased susceptibility of cancer cells to paclitaxel-induced suppression of their viability and further enhanced paclitaxel.induced FOXO3a phosphorylation. These results suggest that the antitumor effects of paclitaxel in breast cancer are mediated by activation of the AMPK/EF1¿/FOXO3a signaling pathway.

KW - Adenosine monophosphate-activated protein kinase

KW - Elongation factor 1 α

KW - Forkhead box O3a

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=84942875532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942875532&partnerID=8YFLogxK

U2 - 10.3892/ijo.2015.3153

DO - 10.3892/ijo.2015.3153

M3 - Article

C2 - 26397839

AN - SCOPUS:84942875532

VL - 47

SP - 1874

EP - 1880

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -